Catalyst Wire Dossier Catalyst Wire Dossier

Obodence

denosumab · Samsung Bioepis NL B.V.
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Obodence, covering 2026-01-06 to 2026-08-04. Get the full timeline:

Most recent: EMA Authorised: Obodence (denosumab) — Samsung Bioepis NL B.V.

See pricing